Clinical Trials

YL-17231, oral panRAS inhibitor

YL-17231 is a clinical-stage panRAS inhibitor that blocks RAS signaling broadly against tumor mutations in KRAS, NRAS, HRAS, and amplified KRAS. Two Phase1 dose escalation clinical trials are exploring the safety and efficacy of YL-17231 in patients with KRAS, NRAS, or HRAS mutations.

NCT06096974, Phase 1 dose escalation trial enrolling in U.S.

NCT06078800, Phase 1 dose escalation trial enrolling in China

YL-15293, oral KRASG12C inhibitor

YL-15293 is a clinical-stage KRASG12C covalent inhibitor that potently and selectively inhibits the KRASG12C oncoprotein. A Phase 1 clinical trial is exploring safety and efficacy in defined KRASG12C-mutated cancers.

NCT05173805, Phase 1 dose escalation in China, on hold